Konakion (Phytomenadione)

Phytomenadione serves as a cofactor for the enzyme that gamma‑carboxylates glutamate residues on clotting factors II, VII, IX and X. This modification enables the factors to bind calcium, which is essential for the formation of the clotting complex and for normal coagulation to occur.

The dose of Konakion is determined by the prescribing clinician based on the patient’s condition, severity of deficiency, and route of administration. Dosage may vary for intravenous versus oral use and is tailored to achieve the desired correction of coagulation parameters.

The safety of Konakion in pregnancy and lactation has not been definitively established. It should be used only when the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To order Konakion, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Konakion (phytomenadione) is a synthetic form of vitamin K1, offering rapid correction of deficiency when given intravenously or orally. Compared with other vitamin K preparations, it provides a well‑characterized pharmacokinetic profile and is commonly used for warfarin reversal, whereas some alternatives may have slower onset or different administration routes.

Konakion should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability, and follow any additional handling instructions provided by the supplier.

Konakion can be administered intravenously as a slow injection or infusion, or given orally in tablet or liquid form, depending on the formulation supplied. The route and rate of administration are determined by the prescriber based on the clinical situation.

Serious risks include anaphylactic reactions, severe bleeding despite treatment, and rare thrombotic events. Patients should be monitored for signs of hypersensitivity, unexpected bleeding, or clot formation, and medical attention should be sought immediately if such symptoms occur.

Konakion should be avoided in individuals with known hypersensitivity to phytomenadione or any component of the formulation. Caution is also advised for patients with severe liver disease, uncontrolled bleeding disorders, or those receiving conflicting anticoagulant therapies without proper monitoring.